Lupin, a Rs.9,450 crore plus fourth largest Indian pharma company, has acquired Nanomi B.V., an independent, privately owned Dutch drug delivery company that develops pharmaceutical products based on nano- and microparticle. With this acquisition, Lupin has made its foray into the technology intensive complex injectables space.
Nanomi has patented technology platforms to develop complex injectable products. Nanomi has a rich talent pool of scientists who would be backed by Lupin’s global R&D and manufacturing teams.
Commenting on the acquisition Vinita Gupta, chief executive officer, Lupin Limited said “We are very pleased with the acquisition of Nanomi. With the use of Nanomi’s proprietary technology platform, Lupin would be able to make significant in - roads into the niche area of complex injectables.”